183 related articles for article (PubMed ID: 37059932)
1. Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer.
Koukourakis IM; Giakzidis AG; Koukourakis MI
Clin Transl Oncol; 2023 Oct; 25(10):3032-3041. PubMed ID: 37059932
[TBL] [Abstract][Full Text] [Related]
2. Ultra-Hypofractionated Re-Irradiation with Anti-PD-1 Immunotherapy for Locoregionally Recurrent (after Radical Chemo-Radiotherapy) Non-Small Cell Lung Cancer.
Filippatos K; Koukourakis IM; Anevlavis S; Giaktzidis A; Koukourakis MI
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894449
[TBL] [Abstract][Full Text] [Related]
3. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
[TBL] [Abstract][Full Text] [Related]
4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
6. Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
Megahed R; Prabhu AV; Mack DP; Gholami S; Samanta S; Patel M; Lewis GD
Oral Oncol; 2024 May; 152():106778. PubMed ID: 38555751
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
Roesch J; Oertel M; Wegen S; Trommer M; Schleifenbaum J; Hering D; Mäurer M; Knippen S; Dobiasch S; Waltenberger M; von der Grün J; Medenwald D; Süß C; Hoeck M; Käsmann L; Fleischmann DF; Rühle A; Nicolay NH; Fabian A; Löser A; Heß S; Tamaskovics B; Vinsensia M; Hecht M;
Radiother Oncol; 2023 Apr; 181():109380. PubMed ID: 36273736
[TBL] [Abstract][Full Text] [Related]
8. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
9. Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes.
Romesser PB; Cahlon O; Scher ED; Hug EB; Sine K; DeSelm C; Fox JL; Mah D; Garg MK; Han-Chih Chang J; Lee NY
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):386-395. PubMed ID: 27084656
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of Re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy.
Hayashi K; Koto M; Ikawa H; Hagiwara Y; Tsuji H; Ogawa K; Kamada T
Radiother Oncol; 2019 Jul; 136():148-153. PubMed ID: 31015117
[TBL] [Abstract][Full Text] [Related]
11. Curative high-dose reirradiation for patients with recurrent head and neck squamous cell carcinoma using IMRT or proton therapy: Outcomes and analysis of patterns of failure.
Beddok A; Saint-Martin C; Krhili S; Eddine CA; Champion L; Chilles A; Goudjil F; Zefkili S; Amessis M; Peurien D; Choussy O; le Tourneau C; Dendale R; Buvat I; Créhange G; Calugaru V
Head Neck; 2022 Nov; 44(11):2452-2464. PubMed ID: 35875934
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
Sahebjam S; Forsyth PA; Tran ND; Arrington JA; Macaulay R; Etame AB; Walko CM; Boyle T; Peguero EN; Jaglal M; Mokhtari S; Enderling H; Raghunand N; Gatewood T; Long W; Dzierzeski JL; Evernden B; Robinson T; Wicklund MC; Kim S; Thompson ZJ; Chen DT; Chinnaiyan P; Yu HM
Neuro Oncol; 2021 Apr; 23(4):677-686. PubMed ID: 33173935
[TBL] [Abstract][Full Text] [Related]
14. A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck.
Ward MC; Lee NY; Caudell JJ; Zajichek A; Awan MJ; Koyfman SA; Dunlap NE; Zakem SJ; Hassanzadeh C; Marcrom S; Boggs DH; Isrow D; Vargo JA; Heron DE; Siddiqui F; Bonner JA; Beitler JJ; Yao M; Trotti AM; Riaz N;
Oral Oncol; 2019 Mar; 90():80-86. PubMed ID: 30846182
[TBL] [Abstract][Full Text] [Related]
15. Re-irradiation Using Intensity-modulated Radiotherapy for Recurrent and Second Primary Head and Neck Cancer.
Choi SH; Chang JS; Choi J; Park SH; Keum KC; Park KR; Lee CG
Anticancer Res; 2018 May; 38(5):3165-3173. PubMed ID: 29715158
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
Tao Y; Faivre L; Laprie A; Boisselier P; Ferron C; Jung GM; Racadot S; Gery B; Even C; Breuskin I; Bourhis J; Janot F
Radiother Oncol; 2018 Sep; 128(3):467-471. PubMed ID: 29784451
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
Hoell PA; Elsayad K; Berssenbruegge H; Hering D; Kittel C; Kleinheinz J; Bleckmann A; Evers G; Wardelmann E; Rudack C; Eich HT
Anticancer Res; 2023 Mar; 43(3):1255-1263. PubMed ID: 36854493
[TBL] [Abstract][Full Text] [Related]
18. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
19. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
Hughes RT; Gebeyehu RR; Kalada JM; Lycan TW; Frizzell BA; Kinney RD; D'Agostino RB; Bunch PM; Triozzi P; Zhang W; Furdui CM; Porosnicu M
Future Oncol; 2023 Jul; 19(22):1523-1534. PubMed ID: 37199326
[TBL] [Abstract][Full Text] [Related]
20. Interventional radiotherapy (brachytherapy) for re-irradiation of recurrent head and neck malignancies: oncologic outcomes and morbidity.
Bussu F; Fionda B; Rigante M; Rizzo D; Loperfido A; Gallus R; De Luca LM; Corbisiero MF; Lancellotta V; Tondo A; D'Aviero A; Mattiucci GC; Kovacs G; Galli J; Tagliaferri L
Acta Otorhinolaryngol Ital; 2024 May; 44(Suppl. 1):S28-S36. PubMed ID: 38745514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
